Literature DB >> 29147276

Conservative Therapy in Two Cases of Non-Hodgkin Lymphoma of the Penis: Case Reports With Review of the Literature.

Giampaolo Delicato1, Giulio Baffigo1, Daniele Bianchi1, Giuseppe Farullo1, Stefano Signore1, Edoardo Tartaglia1, Francesco Corvese1, Vincenzo Ferdinandi1.   

Abstract

The malignant lymphomas rarely occur in the genito-urinary tract and particularly penis lymphomas are extremely uncommon. Frequently they do not have any specific symptoms and the diagnosis is delayed even in presence of a penis node. In our hospital we observed two patients affected by Non-Hodgkin Lymphoma (NHL), one of them with a primitive disease. Both cases were sexually active men who did not accept a radical surgery. A conservative polichemotherapy treatment by ciclophosphamide, vincristine and prednisone has been proposed and performed for both cases and a complete resolution of disease was demonstrated. At the same time we assessed the erectile function by the IIEF score, before and after treatments.

Entities:  

Keywords:  Chemotherapy; Genital localization of lymphoma; Lymphoma of the penis

Year:  2012        PMID: 29147276      PMCID: PMC5649834          DOI: 10.4021/wjon438w

Source DB:  PubMed          Journal:  World J Oncol        ISSN: 1920-4531


Introduction

The genital localization of lymphomas is actually a rare disease. We observed two patients affected by Non-Hodgkin Lymphoma (NHL); we chose a conservative treatment in order to obtain both a good quality of life and good oncological outcomes. We analysed the results with a review of the literature.

Case Report

Over the last 12 months two men (71 years old and 72 years old, respectively) presented with a hard and elastic egg-shaped node of the penis. One of the patients had a history of several recurrences of NHL. We performed an ultrasonography (Fig. 1) with needle biopsy of the lesion in both patients [1] and the pathological examination showed in one case a NHL small cell type and in the other case a NHL mantellar cell type. An abdominal CT scan did not show any evidence of nodal involvement. The two patients were also assessed by the 15 questions-IIEF questionnaire which gave a score of 16 and 18, respectively. So a polichemotherapic treatment by ciclophosphamide, vincristine and prednisone has been decided. We repeated the therapy three times in 40 days. After that we reassessed the two patients by a physical examination and an ultrasonography of the penis. At that moment there was a complete resolution of penile NHL localisation in both patients, though in one of them a leucopenia and splenomegalia occurred and dissuaded from repeating other chemotherapic cycles.
Figure 1

Ultrasonography of the lesion.

Ultrasonography of the lesion. After a follow-up of 4 and 8 months no local disease recurrences occurred. Both patients did not complain any impairment of erectile function as we observed by the IIEF score which was still 15 in the first patient (16 before treatment) and 16 in the second one (16 before treatment).

Discussion

Malignant lymphomas of the penis are rare [2-4] and not associated to specific symptoms or signs [5], even if they could present as small and egg-shaped node [6]. The disease is typical of adults [2], with just one paediatric case in the literature [7]. Surgical removal of these nodes is an easy and effective approach, but it frequently causes esthetical problems and erectile disfunction [8]. So our small experience demonstrated that a conservative treatment is effective both in terms of disease recurrence and functional organ preservation [6, 9]. For these reasons in penile lymphomas a conservative therapy could be considered as the first-choice approach also with a curative goal [10].
  10 in total

1.  Primary lymphoma of the penis: diagnosis and treatment.

Authors:  F Arena; C di Stefano; G Peracchia; A Barbieri; P Cortellini
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

2.  [Primary lymphomas of the urinary in the urological service of the Yaounde Central Hospital].

Authors:  M Sow; P J Fouda; B Nkegoum; J-L Essame Oyono; X S Garau; E Emo Malonga
Journal:  Prog Urol       Date:  2010-10-18       Impact factor: 0.915

3.  [Primary non-Hodgkin's lymphoma of the testis and penis: clinical analysis of 5 cases].

Authors:  Ying-long Li; Qin-zhang Wang; Guo-fu Ding; Ling-xun Li; Zhao Ni; Xin-min Wang
Journal:  Zhonghua Nan Ke Xue       Date:  2011-03

4.  [One case report of primary penile malignant lymphoma (with a review of 24 case reports)].

Authors:  Hai-jun Yao; Jun Ying; Zhong Wang; De-hong Yao; Xiao-min Ren; Yong-yang Bao
Journal:  Zhonghua Nan Ke Xue       Date:  2006-06

5.  Primary B cell non-hodgkin lymphoma of the penis in a child.

Authors:  Chang-Ching Wei; Ching-Tien Peng; I-Ping Chiang; Kang-Hsi Wu
Journal:  J Pediatr Hematol Oncol       Date:  2006-07       Impact factor: 1.289

6.  Successful treatment of primary malignant lymphoma of the penis by organ-preserving rituximab-containing chemotherapy.

Authors:  Shuzo Hamamoto; Keiichi Tozawa; Hideki Nishio; Noriyasu Kawai; Kenjiro Kohri
Journal:  Int J Clin Oncol       Date:  2011-06-28       Impact factor: 3.402

Review 7.  Plasmablastic lymphoma involving the penis: a previously unreported location of a case with aberrant CD3 expression.

Authors:  Jianlan Sun; L Jeffrey Medeiros; Pei Lin; Gary Lu; Carlos E Bueso-Ramos; M James You
Journal:  Pathology       Date:  2011-01       Impact factor: 5.306

8.  [Highly malignant B cell lymphoma as penile tumour].

Authors:  Lars Joachim Lindberg; Ebbe Kvist; Signe Ledou Nielsen
Journal:  Ugeskr Laeger       Date:  2009-11-09

9.  Progressive painless swelling of glans penis: uncommon clinical manifestation of systemic non-Hodgkin's lymphoma.

Authors:  Fernando Gallardo; Ramon M Pujol; Carlos Barranco; Antonio Salar
Journal:  Urology       Date:  2008-06-24       Impact factor: 2.649

Review 10.  [Primary lymphoma of penis].

Authors:  Luis Ibarz Servio; Montserrat Arzoz Fábregas; José M Ruiz Domínguez; Montserrat Batlle Massana; José L Mate Sanz; José Ma Saladié Roig
Journal:  Actas Urol Esp       Date:  2009 Jul-Aug       Impact factor: 0.994

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.